These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10407255)

  • 1. Combining different phases in the development of medical treatments within a single trial.
    Bauer P; Kieser M
    Stat Med; 1999 Jul; 18(14):1833-48. PubMed ID: 10407255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of methods for adaptive sample size adjustment.
    Friede T; Kieser M
    Stat Med; 2001 Dec; 20(24):3861-73. PubMed ID: 11782039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A variational approach to optimal two-stage designs.
    Pilz M; Kunzmann K; Herrmann C; Rauch G; Kieser M
    Stat Med; 2019 Sep; 38(21):4159-4171. PubMed ID: 31264243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of adaptive sample size adjustment with respect to stopping criteria and time of interim analysis.
    Jahn-Eimermacher A; Hommel G
    Stat Med; 2007 Mar; 26(7):1450-61. PubMed ID: 16900553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim treatment selection with a flexible selection margin in clinical trials.
    Wu Y; Zhao PL
    Stat Med; 2013 Jul; 32(15):2529-43. PubMed ID: 23212767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study.
    Bayar MA; Le Teuff G; Koenig F; Le Deley MC; Michiels S
    Stat Methods Med Res; 2020 Jun; 29(6):1483-1498. PubMed ID: 31354106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoothing Corrections for Improving Sample Size Recalculation Rules in Adaptive Group Sequential Study Designs.
    Herrmann C; Rauch G
    Methods Inf Med; 2021 May; 60(1-02):1-8. PubMed ID: 33648007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple and flexible graphical approach for adaptive group-sequential clinical trials.
    Sugitani T; Bretz F; Maurer W
    J Biopharm Stat; 2016; 26(2):202-16. PubMed ID: 25372071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for including patients recruited during interim analysis of clinical trials.
    Faldum A; Hommel G
    J Biopharm Stat; 2007; 17(6):1211-25. PubMed ID: 18027227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing Issues in Confirmatory Adaptive Population Enrichment Trials.
    Wassmer G; Dragalin V
    J Biopharm Stat; 2015; 25(4):651-69. PubMed ID: 24905739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
    Shimura M; Maruo K; Gosho M
    Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tradeoff-based optimization criteria in clinical trials with multiple objectives and adaptive designs.
    Dmitrienko A; Paux G; Pulkstenis E; Zhang J
    J Biopharm Stat; 2016; 26(1):120-40. PubMed ID: 26391238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.